PHARMACODYNAMIC INTERACTION BETWEEN RP-59500 AND GRAM-POSITIVE BACTERIA INFECTING FIBRIN CLOTS

被引:11
作者
TURCOTTE, A
BERGERON, MG
机构
[1] CHU LAVAL,CTR RECH,INFECTIOL LAB,2705 BLVD LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA
[2] UNIV LAVAL,FAC MED,DEPT MICROBIOL,QUEBEC CITY G1K 7P4,QUEBEC,CANADA
[3] CHU LAVAL,CTR RECH,SERV INFECTIOL,QUEBEC CITY G1V 4G2,QUEBEC,CANADA
关键词
D O I
10.1128/AAC.36.10.2211
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The fibrin clot penetration and in vivo bactericidal activity of RP 59500, a new semisynthetic streptogramin, for two Staphylococcus aureus strains (one methicillin resistant and the other methicillin susceptible), two Staphylococcus epidermidis strains (one methicillin resistant and the other methicillin susceptible), and one Enterococcus faecalis strain were evaluated. The clots, inserted subcutaneously, were infected with a mean of 10(8) CFU of the pathogen per g. For each strain, groups of four rabbits received a single intravenous injection of 50 mg of RP 59500 per kg of body weight over 30 min. The mean peak level of RP 59500 in serum in the infected rabbits was 61.9 +/- 6.3 mug/ml. The drug was detectable in serum at a level of 0.8 mug/ml up to 4 h after administration. The mean peak fibrin clot drug level at 1 h was 3.3 +/- 0.1 mug/g. At 6 h, the level in clots was 1.2 +/- 0.1 mug/g. The mean half-life in serum in infected rabbits was 0.34 +/- 0.01 h, while in clots the drug exhibited a longer half-life of 3.8 +/- 0.4 h. In vivo, this new streptogramin sterilized the clots infected with the two S. aureus strains studied in less than 1 h and induced a marked reduction in colony counts of the two S. epidermidis strains studied for up to 24 h. The activity of the streptogramin against E. faecalis was limited. These results suggest that RP 59500 should be further evaluated for the treatment of infection with methicillin-resistant staphylococci.
引用
收藏
页码:2211 / 2215
页数:5
相关论文
共 16 条
[1]  
AUMERCIER M, 1990, 30TH INT C ANT AG CH
[2]  
BERGERON MG, 1981, REV INFECT DIS, V3, P84
[3]  
BRUMFITT W, 1990, 30TH INT C ANT AG CH
[4]  
CHIN NX, 1990, 30TH INT C ANT AG CH
[5]  
CHIN NX, 1991, 31ST INT C ANT AG CH
[6]   PHENOTYPIC AND GENOTYPIC HETEROGENEITY OF GLYCOPEPTIDE RESISTANCE DETERMINANTS IN GRAM-POSITIVE BACTERIA [J].
DUTKAMALEN, S ;
LECLERCQ, R ;
COUTANT, V ;
DUVAL, J ;
COURVALIN, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (10) :1875-1879
[8]  
HOBAN DJ, 1990, 30TH INT C ANT AG CH
[9]   SINGLE ORAL DOSE PHARMACOKINETICS OF THE 2 MAIN COMPONENTS OF PRISTINAMYCIN IN HUMANS [J].
KOECHLIN, C ;
KEMPF, JF ;
JEHL, F ;
MONTEIL, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 (04) :651-656
[10]   INFLUENCE OF 4 MODES OF ADMINISTRATION ON PENETRATION OF AZTREONAM, CEFUROXIME, AND AMPICILLIN INTO INTERSTITIAL FLUID AND FIBRIN CLOTS AND ON INVIVO EFFICACY AGAINST HEMOPHILUS-INFLUENZAE [J].
LAVOIE, GY ;
BERGERON, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (03) :404-412